Keros Therapeutics, Inc. Common Stock (KROS) Stock Price

KROSStock
$11.6830.72%52W
Market Cap$231.58M
P/E2.48x
PEG Ratio
Div yield
Beta1.14

KROS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-44.58%
Price vs S&P 500 (4W)4.00%
VGM Score43.57
P/E Ratio (Annual)2.48x

KROS Earnings Surprise History

Q2 25-0.76est. -1.13
Q3 25-0.18est. -0.92
Q4 25-0.86est. -0.45
Q1 26-1.21est. -0.92
Q2 26-1.45est. -1.24

KROS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.93
3.86
3.86
3.86

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
KROSKeros Therapeutics, Inc. Common Stock
AFC$11.68
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Keros Therapeutics, Inc. Common Stock

Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel protein therapeutics for blood disorders with significant unmet needs. The company's lead program, KER-050, targets cytopenias—including anemia and thrombocytopenia—in patients with myelodysplastic syndromes and myelofibrosis.